BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morse DL, Gillies RJ. Molecular imaging and targeted therapies. Biochem Pharmacol 2010;80:731-8. [PMID: 20399197 DOI: 10.1016/j.bcp.2010.04.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hoehne A, Behera D, Parsons WH, James ML, Shen B, Borgohain P, Bodapati D, Prabhakar A, Gambhir SS, Yeomans DC, Biswal S, Chin FT, Bois JD. A 18 F-Labeled Saxitoxin Derivative for in Vivo PET-MR Imaging of Voltage-Gated Sodium Channel Expression Following Nerve Injury. J Am Chem Soc 2013;135:18012-5. [DOI: 10.1021/ja408300e] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
2 Walker CM, Lee J, Ramirez MS, Schellingerhout D, Millward S, Bankson JA. A catalyzing phantom for reproducible dynamic conversion of hyperpolarized [1-¹³C]-pyruvate. PLoS One 2013;8:e71274. [PMID: 23977006 DOI: 10.1371/journal.pone.0071274] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
3 Rao V, Alleti R, Xu L, Tafreshi NK, Morse DL, Gillies RJ, Mash EA. A sucrose-derived scaffold for multimerization of bioactive peptides. Bioorg Med Chem 2011;19:6474-82. [PMID: 21940174 DOI: 10.1016/j.bmc.2011.08.053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
4 Wei X, Li Y, Zhang S, Gao X, Luo Y, Gao M. Ultrasound targeted apoptosis imaging in monitoring early tumor response of trastuzumab in a murine tumor xenograft model of her-2-positive breast cancer(1.). Transl Oncol 2014;7:284-91. [PMID: 24685547 DOI: 10.1016/j.tranon.2014.02.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Martinez GV, Navath S, Sewda K, Rao V, Foroutan P, Alleti R, Moberg VE, Ahad AM, Coppola D, Lloyd MC, Gillies RJ, Morse DL, Mash EA. Demonstration of a sucrose-derived contrast agent for magnetic resonance imaging of the GI tract. Bioorg Med Chem Lett 2013;23:2061-4. [PMID: 23481651 DOI: 10.1016/j.bmcl.2013.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son DS, Park HW, Yoo HS, Song YJ, Lee E, Oh YM, Lee SB, Choi J, Murray JC, Zhou Y, Song PH, Kim KA, Weiner LM. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 2015;34:1083-93. [PMID: 24662823 DOI: 10.1038/onc.2014.51] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
7 McLean D, Cooke MJ, Albay R 3rd, Glabe C, Shoichet MS. Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-β in TgCRND8 mice. ACS Chem Neurosci 2013;4:613-23. [PMID: 23509918 DOI: 10.1021/cn300226q] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
8 Jeong WJ, Bu J, Kubiatowicz LJ, Chen SS, Kim Y, Hong S. Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms? Nano Converg 2018;5:38. [PMID: 30539365 DOI: 10.1186/s40580-018-0170-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 14.5] [Reference Citation Analysis]
9 Dex S, Alberton P, Willkomm L, Söllradl T, Bago S, Milz S, Shakibaei M, Ignatius A, Bloch W, Clausen-Schaumann H, Shukunami C, Schieker M, Docheva D. Tenomodulin is Required for Tendon Endurance Running and Collagen I Fibril Adaptation to Mechanical Load. EBioMedicine 2017;20:240-54. [PMID: 28566251 DOI: 10.1016/j.ebiom.2017.05.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
10 Wilson B, Geetha KM. Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease. J Control Release 2020;325:25-37. [PMID: 32473177 DOI: 10.1016/j.jconrel.2020.05.044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 McLean D, Cooke MJ, Wang Y, Fraser P, St George-Hyslop P, Shoichet MS. Targeting the amyloid-β antibody in the brain tissue of a mouse model of Alzheimer's disease. J Control Release 2012;159:302-8. [PMID: 22245684 DOI: 10.1016/j.jconrel.2011.12.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
12 Malecki M, Tombokan X, Anderson M, Malecki R, Beauchaine M. TRA-1-60+, SSEA-4+, POU5F1+, SOX2+, NANOG+ Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Testes. J Stem Cell Res Ther 2013;3:1000134. [PMID: 23772337 DOI: 10.4172/2157-7633.1000134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
13 Rejniak KA, Estrella V, Chen T, Cohen AS, Lloyd MC, Morse DL. The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study. Front Oncol 2013;3:111. [PMID: 23717812 DOI: 10.3389/fonc.2013.00111] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
14 Li Y, Yin G, Pu X, Chen X, Liao X, Huang Z. Novel Bi-Functional 14-mer Peptides with Both Ovarian Carcinoma Cells Targeting and Magnetic Fe₃O₄Nanoparticles Affinity. Materials (Basel) 2019;12:E755. [PMID: 30841597 DOI: 10.3390/ma12050755] [Reference Citation Analysis]
15 Delgado-Goñi T, Julià-Sapé M, Candiota AP, Pumarola M, Arús C. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. NMR Biomed 2014;27:1333-45. [PMID: 25208348 DOI: 10.1002/nbm.3194] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
16 Calderon AJ, Bhowmick T, Leferovich J, Burman B, Pichette B, Muzykantov V, Eckmann DM, Muro S. Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J Control Release 2011;150:37-44. [PMID: 21047540 DOI: 10.1016/j.jconrel.2010.10.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
17 Kim M, Gillies RJ, Rejniak KA. Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol 2013;3:278. [PMID: 24303366 DOI: 10.3389/fonc.2013.00278] [Cited by in Crossref: 56] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
18 Qiao J, Xue S, Pu F, White N, Jiang J, Liu ZR, Yang JJ. Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J Biol Inorg Chem 2014;19:259-70. [PMID: 24366655 DOI: 10.1007/s00775-013-1076-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
19 Xue S, Qiao J, Pu F, Cameron M, Yang JJ. Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013;5:163-79. [PMID: 23335551 DOI: 10.1002/wnan.1205] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
20 Ree AH, Redalen KR. Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol 2015;88:20150009. [PMID: 25989697 DOI: 10.1259/bjr.20150009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
21 Xue S, Qiao J, Jiang J, Hubbard K, White N, Wei L, Li S, Liu ZR, Yang JJ. Design of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers. Med Res Rev 2014;34:1070-99. [PMID: 24615853 DOI: 10.1002/med.21313] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
22 Xie X, Ghadimi MP, Young ED, Belousov R, Zhu QS, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, Hornick JL, Lazar AJ, Lev D. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res 2011;17:5901-12. [PMID: 21821699 DOI: 10.1158/1078-0432.CCR-11-0660] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
23 Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol 2013;83:882-93. [PMID: 23371912 DOI: 10.1124/mol.112.084111] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
24 Chalmers KH, Kenwright AM, Parker D, Blamire AM. 19F-lanthanide complexes with increased sensitivity for 19F-MRI: optimization of the MR acquisition. Magn Reson Med 2011;66:931-6. [PMID: 21381109 DOI: 10.1002/mrm.22881] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
25 Zhang A, Sun H, Yang B, Wang X. Predicting new molecular targets for rhein using network pharmacology. BMC Syst Biol 2012;6:20. [PMID: 22433437 DOI: 10.1186/1752-0509-6-20] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
26 Oliveira S, van Dongen GA, Walsum MS, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en Henegouwen PM. Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Anti–Epidermal Growth Factor Receptor Nanobody. Mol Imaging 2012;11:7290.2011.00025. [DOI: 10.2310/7290.2011.00025] [Cited by in Crossref: 110] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]